News

Harvard Bioscience Announces First Quarter 2023 Financial Results

Q1 Revenues of $30 million up 4% over prior year periodQ1 GAAP Operating Income of $1.7 million up from a…

2 years ago

Nexstim Plc’s New Shares Have Been Registered in Trade Register

Company Announcement, Helsinki, 25 April 2023 at 3 PM (EEST) Nexstim Plc’s New Shares Have Been Registered in Trade Register…

2 years ago

Cabaletta Bio to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ

PHILADELPHIA, April 25, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and…

2 years ago

BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, California

VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF…

2 years ago

Vaccinex Completes Enrollment in Phase 1b/2 SIGNAL-AD (Alzheimer’s Disease) Study of Pepinemab

Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER,…

2 years ago

Mary Grace Rutland Joins PetVivo Holdings, Inc. as the Mid-Atlantic Business Development Manager

PetVivo Holdings, Inc. Mary Grace Rutland - New Business Development Manager for the Mid-Atlantic Region of the United StatesMINNEAPOLIS, MN,…

2 years ago

Blue Water Biotech to Participate in the American Urological Association Annual Meeting 2023 to Promote Benign Prostatic Hyperplasia Treatment ENTADFI®

CINCINNATI, April 25, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biotechnology company spanning…

2 years ago

HTG Provides Update on Drug Discovery Partnering Initiative

TUCSON, Ariz., April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools…

2 years ago

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

Promising preliminary antitumor activity with the combination demonstrated in heavily pretreated patients 47% ORR, 5.5 months mPFS observed with preferred…

2 years ago

Rani Therapeutics to Participate in the H.C. Wainwright BioConnect Investor Conference at NASDAQ

SAN JOSE, Calif., April 25, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a…

2 years ago